| Study Supports the Use of Cervista HPV 16/18 Genotyping Test |
|
Analytical performance data from a recent study support the use of the Cervista® HPV 16/18 genotyping test for detection and differentiation of HPV 16 and 18 in ThinPrep cervical cytology specimens. Results from the study were published in the May 2011 issue of Journal of Clinical Virology. The article was co-authored by Dr. Neil Quigley, vice president of clinical research services at MPLN. The article reported the analytical sensitivity (limit of detection), accuracy compared to consensus L1 gene PCR/bi-directional sequencing, precision, reproducibility, and cross-reactivity (specificity) of the genotyping test. Results showed the Cervista test demonstrated high within-laboratory and inter-operator precision. Reproducibility within sites and between three testing sites resulted in 100% agreement with expected results (150 positive, 90 negative results). The genotyping test did not exhibit cross-reactivity to DNA from common low-risk HPV types and other microorganisms found in the human female reproductive tract. To identify and differentiate high-risk HPV types, MPLN offers HPV-high risk testing as well as HPV genotyping. For more information about the tests available to detect HPV, contact a client service specialist at 800.932.2943. |